NCT04173260View on ClinicalTrials.gov

An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

March 15, 2024

Study Completion Date

August 31, 2024

Conditions
Dystonia, Primary
Interventions
DRUG

Deutetrabenazine 6 MG

Increasing doses of Deutetrabenazine

Trial Locations (1)

19107

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

lead

University of Pennsylvania

OTHER